The current work examined the potential of utilizing ARV-825 and ABBV-744 to increase the effectiveness of tamoxifen or fulvestrant plus palbociclib. ARV-825 was effective in both p53 wild-type (WT) breast tumor cells As well as in cells lacking purposeful p53 both alone or in combination with tamoxifen, though the effectiveness https://brd4-targeted-therapy-abb24689.eedblog.com/32105323/abbv-744-cancer-treatment-clinical-trials-an-overview